In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHPA interim president?

This article was originally published in The Rose Sheet

Executive Summary

Consumer Healthcare Products Association reportedly offered board member and healthcare consultant Robert Donovan position of interim president. Donovan, who heads consultancy firm Robert Donovan LLC, formerly led consumer pharmaceuticals business at Sandoz Pharmaceuticals and also worked in consumer products division at Pfizer. He was first elected to CHPA board in 1990. If Donovan accepts, he will succeed Michael Maves, MD, who will leave the association Jan. 15 to head American Medical Association (1"The Rose Sheet" Nov. 26, In Brief)...

You may also be interested in...



CHPA initiates search for president

Consumer Healthcare Products Association is commencing search for a new president after Michael Maves, MD, was appointed to head American Medical Association Nov. 19. Maves will take over as AMA exec VP/CEO effective Jan. 15, departing CHPA after two years. Maves took the helm at CHPA not long after OTC trade group, formerly known as Nonprescription Drug Manufacturers Association, expanded its membership to include dietary supplement companies...

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.

Day One Springs Into Commercial Action With Ojemda Approval

The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel